Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
PEP-Therapy logo — Innovative peptides as targeted therapies for oncology

PEP-Therapy

Innovative peptides as targeted therapies for oncology

Founded 2014 France France 14 employees Series A Total: $7.85M Biotechnology, Health and Wellness

General Information

Company Name PEP-Therapy
Founded Year 2014
Location France France
Employees 14
Industries Biotechnology, Health and Wellness
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with PEP-Therapy. To contact PEP-Therapy, visit pep-therapy.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About PEP-Therapy

PEP-Therapy is a clinical-stage biotechnology company founded in 2014 with a focus on developing innovative peptides as targeted therapies for oncology. Their first drug candidate, PEP-010, has shown promise as a pro-apoptotic agent with demonstrated anti-tumor efficacy in pre-clinical models and a favorable safety profile. Currently, PEP-010 is undergoing evaluation in a Phase Ia/b clinical trial for patients with recurrent and/or metastatic solid tumors. The company's research is based on results from Institut Curie and Sorbonne University, and it has garnered support from international investors, including a recent €1.00M Debt Financing with Bpifrance as the investor at 19 July 2021. Headquartered in France, PEP-Therapy is making strides in the Biotechnology and Health and Wellness industries with its potentially groundbreaking approach to oncology treatment.

Taxonomy: Oncology, Clinical-stage, Targeted therapies, Peptide-based drugs, Cancer research, Cell-penetrating peptides, Pro-apoptotic agents, Intracellular delivery, Protein-protein interactions, Phase Ia/b clinical trial, Metastatic solid tumors, Drug development, Research collaboration, International investment

Services & Products

Development and commercialization of peptide therapies for targeted oncology treatment

Target Customers

Patients with various types of cancer oncologists pharmaceutical companies research institutions

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Pep €1.60M 3
Anaxago BADGE Business Angels des Grandes Ecoles i&i Prague
Anaxago, BADGE Business Angels des Grandes Ecoles +1
19 Jul 2021
Debt Financing Pep €1.00M 1
Bpifrance
Bpifrance
19 Jul 2021
Series A Pep €2.75M 6
Seventure Partners Italian Angels for Growth Doorway Capital
Seventure Partners, Italian Angels for Growth +4
22 Apr 2021
Seed Round Pep €1.20M 2
Seventure Partners
Seventure Partners, Bernard Majoie
16 Nov 2017
Seed Round Pep €1.30M 2
Seventure Partners
Seventure Partners, Bernard Majoie
27 Apr 2015

PEP-Therapy Alternatives & Competitors

View All Alternatives
PEP-Therapy vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
PEP-Therapy vs
Cybrexa Therapeutics
Cybrexa Therapeutics United States

Changing the paradigm for cancer treatment through the development of antigen-independent peptide dr...

Series B
11 employees
Biotechnology, Health and Wellness
PEP-Therapy vs
Arch Oncology
Arch Oncology United States

Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and develop...

Series C
7 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About PEP-Therapy

Innovative peptides as targeted therapies for oncology
PEP-Therapy was founded in 2014.
PEP-Therapy is headquartered in France.
PEP-Therapy operates in Biotechnology and Health and Wellness. Its work centres on Oncology, Clinical-stage, Targeted therapies and Peptide-based drugs. Its customers include Patients with various types of cancer, oncologists and pharmaceutical companies.
PEP-Therapy has approximately 14 employees.
PEP-Therapy has completed 5 funding rounds, raising a total of $7.85M. The latest funding stage is Series A.
PEP-Therapy offers: Development and commercialization of peptide therapies for targeted oncology treatment.
Top alternatives and competitors to PEP-Therapy include Prescient Therapeutics, Cybrexa Therapeutics, Arch Oncology, Orum Therapeutics, Pacylex Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PEP-Therapy and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PEP-Therapy, https://bouncewatch.com/company/pep-therapy, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes